<p><strong>Nutriband Inc.</strong> (NASDAQ:NTRB) 的股东应该对过去一周股价上涨 27% 感到高兴。但这并不能改变过去五年回报令人失望的事实。实际上，股价在这段时间内大幅下跌，下降了约 57%。那么，最近的上涨是否足以恢复对该股票的信心？还不够。然而，在最好的情况下（远非 <em>fait accompli</em>），这种改善的表现可能会持续。</p>
<p>虽然过去五年对 Nutriband 的股东来说很艰难，但过去一周却显示出一些希望的迹象。那么，让我们看看长期的基本面，看看它们是否是负回报的驱动因素。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前入场。</p>
<p>Nutriband 在过去 12 个月内没有盈利，因此其股价与每股收益（EPS）之间不太可能存在强相关性。可以说，收入是我们下一个最佳选择。无盈利公司的股东通常希望看到强劲的收入增长。这是因为快速的收入增长可以很容易地推断出利润，通常是相当可观的。</p>
<p>在过去五年中，Nutriband 的收入每年增长 16%。这比大多数亏损公司要好。相比之下，股价平均每年损失 9%——这相当令人失望。这可能意味着高期望已经被抑制，可能是因为投资者在关注底线。如果你认为公司能够保持收入增长，你就必须考虑这里可能存在机会。</p>
<p>公司的收入和盈利（随着时间的推移）在下图中展示（点击查看具体数字）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/345353860-earnings-and-revenue-growth-1-dark-2/1767090025716?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/345353860-earnings-and-revenue-growth-1-dark-2/1767090025716"/></p>
<p>NasdaqCM:NTRB 收益和收入增长 2025 年 12 月 30 日</p>
<p>通过这份 <strong>免费</strong> 的资产负债表报告，更全面地了解 Nutriband 的财务健康状况。</p>
<h2>不同的视角</h2>
<p>很高兴看到 Nutriband 在过去 12 个月内为股东带来了 33% 的总股东回报。值得注意的是，五年年化总股东回报损失为每年 9%，与近期的股价表现相比非常不利。长期的损失让我们保持谨慎，但短期的总股东回报增长无疑暗示着更光明的未来。我发现从长期来看观察股价作为商业表现的代理非常有趣。但要真正获得洞察，我们还需要考虑其他信息。例如，投资风险的无处不在的阴影。<strong>我们已经识别出 Nutriband 的 4 个警告信号</strong>（至少有 2 个让我们感到不安），理解这些信号应该是你投资过程的一部分。</p>
<p>当然，<strong>你可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 所以请查看这份 <strong>免费</strong> 的公司名单，我们预计这些公司将会增长盈利。</p>
<p><em>请注意，本文中引用的市场回报反映了目前在美国交易所上市股票的市场加权平均回报。</em></p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是人形的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随处可用。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

NTRB

<p>Nutriband Inc.（纳斯达克代码：NTRB）股票在过去一周上涨了 27%，但在过去五年中下跌了 57%。尽管近期有所上涨，但长期表现仍然令人失望，年化损失为 9%。在此期间，收入年增长率为 16%，好于许多未盈利公司。过去一年的总股东回报率为 33%，显示出复苏的潜力。然而，由于与公司相关的风险已被识别，建议保持谨慎</p>

<p><strong>Nutriband Inc.</strong> (NASDAQ:NTRB) shareholders should be happy to see the share price up 27% in the last week. But that doesn't change the fact that the returns over the last half decade have been disappointing. In fact, the share price has declined rather badly, down some 57% in that time. So is the recent increase sufficient to restore confidence in the stock? Not yet. However, in the best case scenario (far from <em>fait accompli</em>), this improved performance might be sustained.</p>
<div class="lb-trans"><p><strong>Nutriband Inc.</strong> (NASDAQ:NTRB) 的股东应该对过去一周股价上涨 27% 感到高兴。但这并不能改变过去五年回报令人失望的事实。实际上，股价在这段时间内大幅下跌，下降了约 57%。那么，最近的上涨是否足以恢复对该股票的信心？还不够。然而，在最好的情况下（远非 <em>fait accompli</em>），这种改善的表现可能会持续。</p>
</div><p>While the last five years has been tough for Nutriband shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.</p>
<div class="lb-trans"><p>虽然过去五年对 Nutriband 的股东来说很艰难，但过去一周却显示出一些希望的迹象。那么，让我们看看长期的基本面，看看它们是否是负回报的驱动因素。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前入场。</p>
</div><p>Nutriband wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.</p>
<div class="lb-trans"><p>Nutriband 在过去 12 个月内没有盈利，因此其股价与每股收益（EPS）之间不太可能存在强相关性。可以说，收入是我们下一个最佳选择。无盈利公司的股东通常希望看到强劲的收入增长。这是因为快速的收入增长可以很容易地推断出利润，通常是相当可观的。</p>
</div><p>In the last half decade, Nutriband saw its revenue increase by 16% per year. That's better than most loss-making companies. In contrast, the share price is has averaged a loss of 9% per year - that's quite disappointing. This could mean high expectations have been tempered, potentially because investors are looking to the bottom line. If you think the company can keep up its revenue growth, you'd have to consider the possibility that there's an opportunity here.</p>
<div class="lb-trans"><p>在过去五年中，Nutriband 的收入每年增长 16%。这比大多数亏损公司要好。相比之下，股价平均每年损失 9%——这相当令人失望。这可能意味着高期望已经被抑制，可能是因为投资者在关注底线。如果你认为公司能够保持收入增长，你就必须考虑这里可能存在机会。</p>
</div><p>The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).</p>
<div class="lb-trans"><p>公司的收入和盈利（随着时间的推移）在下图中展示（点击查看具体数字）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/345353860-earnings-and-revenue-growth-1-dark-2/1767090025716" alt="" original-src="https://images.simplywall.st/asset/chart/345353860-earnings-and-revenue-growth-1-dark-2/1767090025716"/></p>
<p>NasdaqCM:NTRB Earnings and Revenue Growth December 30th 2025</p>
<div class="lb-trans"><p>NasdaqCM:NTRB 收益和收入增长 2025 年 12 月 30 日</p>
</div><p>Take a more thorough look at Nutriband's financial health with this <strong>free</strong> report on its balance sheet.</p>
<div class="lb-trans"><p>通过这份 <strong>免费</strong> 的资产负债表报告，更全面地了解 Nutriband 的财务健康状况。</p>
</div><h2>A Different Perspective</h2>
<div class="lb-trans"><h2>不同的视角</h2>
</div><p>It's good to see that Nutriband has rewarded shareholders with a total shareholder return of 33% in the last twelve months. Notably the five-year annualised TSR loss of 9% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. <strong>We've identified 4 warning signs</strong> with Nutriband (at least 2 which don't sit too well with us) , and understanding them should be part of your investment process.</p>
<div class="lb-trans"><p>很高兴看到 Nutriband 在过去 12 个月内为股东带来了 33% 的总股东回报。值得注意的是，五年年化总股东回报损失为每年 9%，与近期的股价表现相比非常不利。长期的损失让我们保持谨慎，但短期的总股东回报增长无疑暗示着更光明的未来。我发现从长期来看观察股价作为商业表现的代理非常有趣。但要真正获得洞察，我们还需要考虑其他信息。例如，投资风险的无处不在的阴影。<strong>我们已经识别出 Nutriband 的 4 个警告信号</strong>（至少有 2 个让我们感到不安），理解这些信号应该是你投资过程的一部分。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking elsewhere.</strong> So take a peek at this <strong>free</strong> list of companies we expect will grow earnings.</p>
<div class="lb-trans"><p>当然，<strong>你可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 所以请查看这份 <strong>免费</strong> 的公司名单，我们预计这些公司将会增长盈利。</p>
</div><p><em>Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.</em></p>
<div class="lb-trans"><p><em>请注意，本文中引用的市场回报反映了目前在美国交易所上市股票的市场加权平均回报。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是人形的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随处可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

Nutriband（NASDAQ:NTRB）的股东在过去一周内股价上涨了 27%，但在过去五年中仍然亏损